


Participant flow



Baseline characteristics

Table 2 Participant characteristics.				
		Control Group	Intervention Group	p*
Mean age years (+/- SD)		38.89 (6.60)	39.00 (8.44)	0.84
Gender, n				
	Male	8	9	0.737
	Female	1	1	
Education level, n				
	Primary	2	1	0.49
	Secondary	3	6	
	Tertiary	4	3	
Occupation, n				
	Unemployed	0	0	0.21
	Retired	7	10	
	Employed	1	0	
	Student	1	0	
Marital status, n				
	Single	9	10	0.93
	Married	0	0	
	Separated	0	0	
	Widowed/Other	0	0	
Mean age at		24.67 (6.65)	23.60 (5.75)	0.78

diagnosis (+/-SD)				
Medication dosis, mg of chlorpromazine (SD)		355.18 (205.6)	344.15 (143.2)	0.72
Hospital admissions, n (+/-SD)		2.33 (3.04)	3.20 (4.36)	0.60
PANSS-P		21.22 (3.93)	16.60 (2.98)	0.017**
PANSS-N		24.78 (2.33)	25.00 (6.36)	0.96
PANSS-C		- 3.22 (2.53)	- 8.40 (6.73)	0.028**
PANSS-PG		47.00 (7.73)	40.70 (7.00)	0.079

p-value: U Mann-Whitney.

** $p < 0.05$ = statistical significance.

Abbreviations: P, Positive; N, Negative; C, Composite; PG: General Psychopathology scales

Voc, Vocabulary; Mat, Matrices; Comp, Composite.

Outcome measures

Primary outcome measures

Table 3. ANCOVA post–pre changes scores							
	Control Group		InterventionGroup		F	P value	Efect size η^2_{pre}
	Mean IC95%	SD	Mean IC95%	SD			
Ekman Total pre	44,67[41,64;47,69]	3.94	43,80 [40,05; 47,55]	5.25			
Ekman Total post	46,44[42,62;50,27]	4.98	47,00 [42,59; 51,41]	6.16			
Change Ekman Total	1,78[-1,78;5,34]	4.63	3,20 [0,80; 5,60]	3.36	4.072	0,036**	0.324
ER 40 TOTAL pre	27,22[24,13;30,32]	4.02	27,90 [25,24; 30,56]	3.73			
ER 40 TOTAL post	28,00[24,35;31,65]	4.74	30,90 [28,65; 33,15]	3.14			
Change ER 40 TOTAL	0,78[-2,27;3,82]	3.96	3,00 [1,65; 4,35]	1.89	5.149	0,018**	0.377

** p<0.05 = statistical significance

Table 4. Scores Ekman60 pre and post intervention.						
	Control Group			Intervention Group		
	Pre Mean (SD)	Post Mean (SD)	p*	Pre Mean (SD)	Post Mean (SD)	p*
Ekman Total	44.67 (3.93)	46.44 (4.97)	0.572	43.80 (5.24)	47.00 (6.16)	0.024**
Happiness	9.89 (0.33)	10.00 (0.00)	0.317	10.00 (0.00)	9.80 (0.42)	0.157
Surprise	8.11 (1.36)	7.78 (1.09)	0.334	8.10 (1.79)	8.20 (0.91)	0.914
Fear	6.44 (2.29)	6.11 (2.93)	0.550	5.00 (2.26)	5.90 (2.37)	0.133

Sadness	6.44 (1.66)	7.44 (2.45)	0 .260	7.30 (1.56)	7.80 (1.68)	0 .476
Disgust	6.89 (1.26)	7.89 (1.83)	0 .119	6.10 (3.07)	6.80 (2.74)	0 .083
Anger	6.89 (2.57)	7.22 (2.22)	0 .595	7.30 (0.67)	8.50 (1.50)	0 .037**

* p-value: Wilcoxon test.

** p < 0.05 = statistical significance.

Table 5. Scores ER40 pre and post intervention.						
	Control Group			Intervention Group		
	Pre Mean (SD)	Post Mean (SD)	p*	Pre Mean (SD)	Post Mean (SD)	p*
ER40 Total	27.22 (4.02)	28.00 (4.74)	0 .343	27.90 (3.72)	30.90 (3.14)	0 .011**
Happiness	7.67 (0.50)	7.67 (0.70)	0.999	7.30 (0.67)	7.50 (0.85)	0 .527
Fear	4.67 (1.87)	4.56 (1.59)	0 .731	5.60 (1.17)	5.70 (0.67)	0 .739
Sadness	6.00 (1.58)	6.33 (1.41)	0 .595	6.30 (1.76)	7.10 (1.85)	0 .057
Anger	2.56 (1.33)	3.11 (1.36)	0 .317	3.10 (1.10)	3.30 (0.82)	0 .589
Neutral	6.33 (1.80)	6.33 (1.87)	0 .931	5.60 (2.98)	7.30 (2.11)	0 .014**

* p-value: Wilcoxon test.

** p < 0.05 = statistical significance.

Secondary outcome measures

Table 4.	Scores pre and post intervention.					
	Control Group			Intervention Group		
	Pre Mean (SD)	Post Mean (SD)	p*	Pre Mean (SD)	Post Mean (SD)	p*
PANSS-P	21.22 (3.93)	21.22 (3.93)	0.99	16.60 (2.98)	16.60 (2.98)	0.99
PANSS-N	24.78 (2.33)	24.78 (2.33)	0.99	25.00 (6.36)	24.60 (6.63)	0.99
PANSS-C (-)	3.22 (2.53)	3.56 (2.96)	0.317	8.40 (6.73)	8.00 (6.91)	0.99
PANSS-PG	47.00 (7.73)	47.00 (7.73)	0.99	40.70 (7.00)	40.70 (7.00)	0.99
K-BIT Voc	112.25 (11.60)	118.25 (7.70)	0.068	104.60 (16.74)	110.60 (17.82)	0.050**
K-BIT Mat	101.13 (12.48)	97.75 (17.99)	0.400	97.50 (19.01)	98.80 (19.82)	0.77
K-BIT Comp	105.13 (12.98)	106.75(12.45)	0.308	98.70 (18.69)	93.60 (36.21)	0.77
P: Positive scale. N: Negative scale. C: Composite scale. PG: General Psychopathology scale Voc: Vocabulario. Mat: Matrices. Comp: Compuesto * p-value: Wilcoxon test. ** p < 0.05 = statistical significance.						

Adverse events

There were no adverse events associated with this trial.